Cellectis (EPA:ALCLS), (NASDAQ:CLLS) is a biopharmaceutical company focused on developing immunotherapies based on gene-edited T-cells, using its pioneering TALEN technology and CRISPR-Cas9. The company is headquartered in Paris, France, and operates globally, aiming to harness the power of the immune system to target and eradicate cancers. Cellectis is also known for its innovative approach in the field of gene editing, endeavoring to create more effective and safer therapies for patients worldwide. Its project portfolio includes multiple pre-clinical and clinical trials, focusing primarily on CAR-T cell therapies, a groundbreaking approach in cancer treatment. Cellectis is driven by the objective to make accessible life-saving UCART product candidates to address unmet needs in the treatment of multiple aggressive cancers.